LACTOLOGY FOUNDATION

Papaverine and its derivatives (ATC A03AD) are non‑opioid antispasmodic vasodilators used mainly for visceral smooth‑muscle spasms and certain vasospastic states. Toxicological and lactation data are limited, but available evidence suggests cautious use in pregnancy and breastfeeding, with preference for short‑term, lowest‑effective dosing and close clinical monitoring.medpedia.framar+8

Pharmacological group and members

The ATC class A03AD “Papaverine and derivatives” comprises papaverine (A03AD01), drotaverine (A03AD02) and moxaverine (A03AD30). These drugs are classified under A03 “Drugs for functional gastrointestinal disorders,” reflecting their primary indication for gastrointestinal and biliary smooth‑muscle spasm.atcddd.fhi+1

Papaverine is an opium alkaloid structurally distinct from morphine‑like opioids and acts as a direct‑acting smooth‑muscle relaxant and vasodilator. Drotaverine and moxaverine are synthetic papaverine analogues designed to provide spasmolytic and vasodilatory effects with modified pharmacokinetics and tolerability; both are used in several countries for gastrointestinal, biliary, genitourinary and vascular spasm.drugbank+4

Mechanism of action

Papaverine inhibits phosphodiesterase (mainly non‑selective), increasing intracellular cAMP and cGMP and thereby promoting smooth‑muscle relaxation in vascular and visceral beds. This leads to reduction of gastrointestinal, biliary, ureteral and vascular tone and relief of spasm‑related pain, as well as vasodilation in cerebral and peripheral arteries.drugs.ncats+2

Drotaverine exhibits spasmolytic activity through selective inhibition of phosphodiesterase‑4 and modulation of calcium influx in smooth muscle, which decreases contractility independently of autonomic innervation. Moxaverine similarly acts as a phosphodiesterase inhibitor and vasodilator, improving microcirculatory blood flow, particularly in ocular and peripheral vascular disorders.drugbank

Therapeutic indications

A03AD agents are indicated for functional gastrointestinal and biliary disorders such as intestinal, biliary and ureteral colic, where smooth‑muscle spasm is a prominent component. In addition, papaverine is approved or used as adjunctive therapy in vasospastic conditions, including cerebral and coronary vasospasm, peripheral vascular disease, and certain states of myocardial ischemia complicated by arrhythmias.drugbank+3

Papaverine is also used intra‑arterially during neurosurgical and vascular procedures (for example, in subarachnoid hemorrhage–related vasospasm or coronary artery bypass grafting) to achieve local vasodilation. Drotaverine is widely used for dysmenorrhea, irritable bowel–type symptoms and biliary dyskinesia, whereas moxaverine has niche use in ocular and peripheral circulatory impairment.wikipedia+4

Dosing overview and exposure determinants

Oral papaverine doses in adults commonly range from 100 to 300 mg three to five times daily, with extended‑release regimens of 150 mg every 12 hours and a maximum daily dose around 600 mg in clinical practice. Parenteral papaverine (intravenous, intra‑arterial or intramuscular) is typically administered as 30–120 mg every three hours, or single intra‑arterial doses around 40 mg given slowly over 1–2 minutes.mayoclinic+3

High total daily doses, rapid intravenous administration, impaired hepatic function and concomitant cardiovascular disease are major determinants of systemic exposure and toxicity risk. For lactation risk assessment, repeated high oral doses and continuous parenteral infusions are more likely to ensure steady maternal plasma levels and potential milk transfer than short procedural boluses.ncbi.nlm.nih+4

General toxicology

Therapeutic papaverine can cause cutaneous flushing, sweating, nausea, constipation, dizziness, headache, hypotension, tachycardia, diplopia and elevated liver enzymes; rare cases of clinically significant hepatotoxicity have been reported. Serious hypersensitivity reactions, including urticaria, angioedema and bronchospasm, as well as conduction disturbances and ventricular arrhythmias, have been described particularly with parenteral use or overdose.simsrc+2

Acute papaverine poisoning may present with CNS depression, coma, respiratory depression, seizures, marked hypotension, arrhythmias and metabolic disturbances. Management is supportive, including airway protection, circulatory support with fluids and vasopressors, seizure control with benzodiazepines or other anticonvulsants, and decontamination (activated charcoal and gastric lavage) when appropriate; hemodialysis has been suggested as potentially useful in some cases.e-lactancia+1

Contraindications and cautions

Use of papaverine is contraindicated in patients with hypersensitivity to the drug, significant atrioventricular conduction disturbances, recent myocardial infarction or stroke, and narrow‑angle glaucoma. The drug should be used cautiously in hypotension, hepatic impairment and in patients with a history of ventricular arrhythmias or prolonged QT interval.rxlist+2

Concomitant administration of papaverine with levodopa can antagonize the antiparkinsonian effect of levodopa, necessitating clinical monitoring and possible therapeutic adjustment. Simultaneous use with sulfonamides is discouraged in some product information, and general caution is warranted with other vasodilators, antihypertensives and agents that depress cardiac conduction.medpedia.framar+2

Pregnancy safety

Recent large population‑based cohort data suggest that papaverine exposure during pregnancy, including first‑trimester use, is not associated with an increased risk of major congenital malformations or specific organ‑system malformations compared with unexposed pregnancies. These studies also did not detect significant associations between third‑trimester exposure and late adverse pregnancy outcomes such as preterm birth or low birth weight.pmc.ncbi.nlm.nih+1

Despite these reassuring observational data, regulatory documents and reviews often still categorize papaverine as pregnancy category C and recommend cautious, individualized use, particularly in early gestation and in the presence of maternal cardiovascular disease. For drotaverine and moxaverine, pregnancy data are more limited; they are generally used short term for severe colicky pain when benefits outweigh uncertainties, with preference for minimal effective dosages.e-lactancia+2

Lactation: papaverine

No direct quantitative data were found on papaverine concentrations in human breast milk or on infant serum levels. Based on pharmacokinetic properties—relatively large volume of distribution, high protein binding and short plasma half‑life—clinically significant transfer of papaverine into breast milk is considered unlikely, especially with intermittent low‑dose use.e-lactation+3

Authoritative drug and lactation databases advise that papaverine should be used cautiously during breastfeeding, particularly in mothers of newborn or preterm infants, due to the absence of direct clinical data and the potential for cardiovascular and CNS effects. Product labeling similarly recommends exercising caution when papaverine is administered to nursing women and emphasizes individualized risk–benefit assessment.ncbi.nlm.nih+2

Lactation: derivatives (drotaverine, moxaverine)

For drotaverine and moxaverine, no specific milk‑transfer or infant outcome studies were identified. Given their similar mechanism and systemic vasodilatory/spasmolytic effects, it is prudent to extrapolate a cautious approach, especially for repeated dosing or high cumulative exposure in mothers of very young or medically fragile infants.e-lactation+1

When antispasmodic therapy is required during lactation, short‑term use of the lowest effective dose, avoidance of parenteral boluses unless clearly indicated, and clinical monitoring of the breastfed infant for excessive sedation, feeding difficulties, hypotonia or unusual irritability are advisable. In full‑term healthy infants, brief maternal treatment courses are unlikely to pose significant risk, though alternatives with better established lactation profiles may be preferred when available.ncbi.nlm.nih+2

Lactotoxicological risk factors

Key lactotoxicological risk factors for A03AD drugs include:

• High maternal doses and long treatment duration, which increase the likelihood of sustained plasma and potential milk levels.drugbank+2
• Parenteral administration (intravenous or intra‑arterial), which leads to higher peak concentrations and greater risk of cardiovascular instability in the mother.simsrc+2
• Maternal hepatic or renal impairment, potentially reducing clearance and prolonging half‑life, with uncertain effects on milk excretion.drugbank+1

From the infant side, preterm birth, low birth weight, underlying cardiac or hepatic disease, and concurrent exposure to other cardioactive or CNS‑active drugs may amplify vulnerability to even small amounts of transferred papaverine or derivatives. In neonates, immature hepatic metabolism and blood–brain barrier can increase susceptibility to hypotension, arrhythmias or CNS depression.e-lactation+1

Clinical monitoring and management in breastfeeding

When a lactating patient receives papaverine or an A03AD derivative, clinicians should:

• Review indication and consider non‑pharmacological measures or alternative agents with better lactation data where feasible.ncbi.nlm.nih+1
• Use the minimal effective dose for the shortest duration, avoiding repeated high‑dose parenteral regimens if oral therapy suffices.e-lactancia+1

Infant monitoring should focus on: feeding pattern and weight gain; level of alertness; skin color and perfusion; and any episodes of apparent apnea, cyanosis or poor responsiveness. If concerning symptoms occur temporally related to maternal dosing, temporary interruption of breastfeeding and medical evaluation of the infant are recommended, with consideration of drug discontinuation or substitution in the mother.e-lactation+1

Summary risk assessment

Overall, papaverine and its derivatives in class A03AD can be considered compatible with breastfeeding under cautious, short‑term use in healthy full‑term infants, though the evidence base is weak and largely inferential rather than based on direct milk studies. For newborn, preterm or medically fragile infants, or where prolonged high‑dose therapy is anticipated, alternative antispasmodics with more robust lactation safety data should be prioritized when clinically appropriate.drugbank+2

During pregnancy, current cohort data for papaverine are reassuring with respect to congenital malformations and major adverse outcomes, supporting its use when clearly indicated, albeit still within a framework of careful benefit–risk evaluation and avoidance of unnecessary exposure. In all cases, a case‑by‑case toxicological and lactological assessment, incorporating maternal comorbidities, concomitant medications and infant vulnerability, remains essential.cris.bgu+2